Nausea is a condition usually associated with motion sickness, dizziness, and vomiting. Nausea medicines are used to treat symptoms of nausea and prevent vomiting. Common classes of nausea medicines include antihistamines, anticholinergics, phenothiazines, cannabinoids, and 5-HT3 receptor antagonists. Antihistamines like dimenhydrinate and meclizine are over-the-counter medicines commonly used for nausea relief. Prescription nausea medicines include ondansetron, granisetron, and dolasetron which work by blocking serotonin receptors in the body. The growing prevalence of conditions that cause nausea like migraine, chemotherapy, pregnancy, and gastrointestinal disorders is increasing the demand for effective nausea treatments.
The global Nausea Medicine Market is estimated to be valued at US$ 2.8 Bn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/nausea-medicine-market-6064
Market key trends:
One of the key trends in the nausea medicine market is the increased research and development of novel drug formulations and drug delivery methods. For instance, companies are developing transdermal patches, sublingual tablets, and orally disintegrating tablets to overcome challenges associated with oral drugs like delayed onset of action and unpredictable absorption. Transdermal patches provide sustained delivery of antiemetics and help avoid the gastrointestinal route. Sublingual tablets and orally dissolving formulations dissolve rapidly in the mouth enabling faster absorption and relief from nausea. Another important trend is the focus on developing highly selective serotonin 5-HT3 receptor antagonists and neurokinin-1 receptor antagonists with improved side effect profiles compared to existing therapies. Constant innovations aimed at enhancing efficacy, safety, and patient compliance are expected to boost the nausea medicine market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: Low due to high capital requirement in RD and regulations.
Bargaining power of buyers: High due to availability of alternative treatments.
Bargaining power of suppliers: Moderate due to availability of substitutes and regulations.
Threat of new substitutes: Moderate threat from generic drugs, herbal and over-the-counter treatments.
Competitive rivalry: Intense competition among existing pharmaceutical companies.
Key Takeaways
The global Nausea Medicine Market is expected to witness high growth. The global Nausea Medicine Market is estimated to be valued at US$ 2.8 Bn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030.
Regional analysis related content comprises the North America region currently dominates the market and is expected to retain its position throughout the forecast period due to advanced healthcare infrastructure and presence of major players. Asia Pacific is expected to witness fastest growth due to rising healthcare expenditure and growing awareness.
Key players operating in the Nausea Medicine market are GlaxoSmithKline plc., Pfizer Inc., Novartis International AG, Sanofi S.A., Merck Co., Inc., Johnson Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc., and Eli Lilly and Company. GlaxoSmithKline plc holds the leading market share in the nausea medicine market owing to its effective drugs and strong distribution networks worldwide. Takeda Pharmaceutical Company and Sanofi S.A are also among the top players due to presence across regions and robust product portfolio.
